Meningococcal Group A, C Bivalent Polysaccharide Conjugate Vaccine

Specification

• Cat#: VAC-0380
• Product Name: Meningococcal Group A, C Bivalent Polysaccharide Conjugate Vaccine
• Description: This vaccine is with meningococcal A 29201 strains, 29205 strains of group C meningococcal respectively by fermentation, purification of capsular polysaccharide antigens, after polysaccharide activation, derivative with tetanus toxoid protein covalent bonding is A group of polysaccharides and protein binders and C group of polysaccharide and protein, according to A certain mixing ratio, after lyophilization in adding the suitable stabilizer.
• Formulation: Each 0. 5ml contains:Group A meningococcal capsular polysaccharide 10μg Group C meningococcal capsular polysaccharide 10μg Tetanus toxoid protein 33～120μg lactose 3～5mg sodium chloride 3. 75～4. 75mg Diluent: sterilizing water for injection
• Storage: Store and transport from 2°C to 8°C out of light.
• Function: The vaccine is used to prevent infectious diseases caused by group A and C meningococci, such as cerebrospinal meningitis septicemia (systemic infection). The vaccine does not prevent infection caused by other groups of meningococci or other pathogens that cause meningitis or septicemia